Piper Sandler lowered the firm’s price target on Arvinas to $70 from $81 and keeps an Overweight rating on the shares post the Q2 report. The analyst pushed out vepdegestrant and bavdegalutamide approvals, which resulted in the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas price target lowered to $39 from $70 at Barclays
- Arvinas expects cash to fund operations into 2026
- Arvinas reports Q2 EPS ($1.25), consensus ($1.65)
- Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Arvinas & Pfizer win UK Innovation award in UK for Vepdegestrant